Patent pools: an easy licensing option for COVID-19 drugs and SARS CoV 2 vaccines?
An exploration of patent pools, R&D and current initiatives.
by Dr. Anja Lunze, LL.M. and Dr. Jan Phillip Rektorschek
2 of 6 Insights
Termination, force majeure and frustration – international perspectives on the life sciences sector
by multiple authors
COVID-19 and life sciences M&A
by multiple authors
Marketing authorisation and clinical testing of new drugs
Competition law issues shaping the pharmaceutical sector
by Paolo Palmigiano and Louisa Penny
Special approvals of the Federal Institute for Drugs and Medical Devices for the distribution of medical devices and FFP breathing masks without an expiration valve
Restrictions for patents owners to preserve the public interest in the sufficient availability of necessary medicinal products
GDPR and life sciences – part 2
The Bolar and related exemptions in Europe
What activity do they cover?
by multiple authors